Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
May 10, 2021
Date of Patent:
February 20, 2024
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence to either enable or prevent a flow of fluid through various fluid flow lines.
Type:
Grant
Filed:
September 4, 2020
Date of Patent:
August 2, 2022
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin, Timothy Jon Perlman
Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
September 15, 2020
Date of Patent:
June 15, 2021
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin
Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
November 3, 2020
Assignee:
HDL Therapeutics, Inc.
Inventors:
Hollis Bryan Brewer, Jr., Michael M. Matin